Acarbose

Overview

Acarbose is an oral anti-hyperglycemic agent used as an adjunct therapy in diabetic dogs and cats, especially when post-prandial blood glucose spikes persist despite insulin treatment. It helps smooth the glucose curve in patients with rapid rises after meals.

The drug acts locally within the gastrointestinal tract with minimal systemic absorption. Its clinical benefit is greatest when given with meals that contain a moderate to high carbohydrate content and when owners can reliably time dosing with feeding.

Mechanism of Action (MOA): Acarbose competitively inhibits pancreatic alpha-amylase and the alpha-glucosidases of the small intestine, slowing the breakdown of complex carbohydrates and disaccharides and delaying glucose absorption. It has no effect on lactase and does not stimulate insulin secretion. This blunts post-meal hyperglycemia and reduces blood-glucose fluctuations in diabetic animals.

Indications

Acarbose is used as an adjunct therapy in the management of diabetes mellitus in dogs and cats, particularly when post-prandial hyperglycemia remains high despite appropriate insulin dosing. It is most useful in patients that show rapid glucose spikes after meals.

• Post-prandial glucose control: Helps flatten post-meal glucose curves when insulin alone is insufficient.
• Patients on high-carbohydrate diets: Especially beneficial when dietary adjustments are limited or when animals are reluctant to switch foods.
• Cats with fluctuating glucose curves: May help reduce variability when mealtime peaks create instability.
• Dogs with persistent hyperglycemia: Useful when increasing insulin dose is not appropriate due to hypoglycemia risk.
• Adjunct to improve overall glycemic stability: Not a replacement for insulin, but can improve control when used with consistent feeding schedules.

Dosage (Reference)

Dog

Acarbose dosing in dogs is based on fixed mg-per-dog amounts rather than mg/kg. It is given with meals to slow carbohydrate absorption and reduce post-prandial glucose spikes.

Cat

Cats receive a fixed 12.5 mg dose twice daily with a meal, regardless of body weight. It is most effective when appetite is good and meals are consistent.

Warnings & Precautions

Acarbose is generally well-tolerated but must be used carefully in diabetic animals, especially those with gastrointestinal disease or poor appetite. Its effect depends on adequate food intake and normal intestinal motility.

• GI disease: Avoid in patients with IBD, colonic ulceration, partial obstruction, or severe gastrointestinal inflammation due to risk of worsening symptoms.
• Poor appetite: The drug is ineffective when food intake is low; doses should be skipped if the animal does not eat.
• Diabetic ketoacidosis: Contraindicated in DKA; insulin therapy is required for stabilization.
• Underweight animals: Underweight animals: Contraindicated in patients with low body weight, because acarbose reduces calorie absorption and can worsen nutritional status. In normal-weight patients, monitor body condition during therapy and discontinue if weight loss develops.
• Liver & kidney disease : Mild increases in liver enzymes can occur; monitor ALT/AST during therapy. Also use cautiously if renal disease is present
• Flatulence and soft stools: Very common due to carbohydrate fermentation; usually dose-dependent and improves with time or dose reduction.
• Drug timing: Must be given with the first bite of food for proper effect.
• Concurrent hypoglycemics: When combined with insulin or sulfonylureas, monitor closely for hypoglycemia post-meal.

Drug Interactions

Acarbose has a small number of clinically relevant interactions in veterinary patients. Most involve changes in glucose levels or gastrointestinal effects.

• Insulin / sulfonylureas: Combined therapy increases the risk of post-meal hypoglycemia. Monitor blood glucose closely and adjust insulin dose if needed.
• Absorbents (e.g., charcoal, digestive adsorbents): May reduce acarbose’s effect by decreasing its availability in the gut.
• Digestive enzyme supplements: Products containing amylase or pancreatin can counteract acarbose and reduce its glucose-lowering action.
• Digoxin: Acarbose may reduce digoxin blood concentrations. If acarbose is started in a patient on digoxin, monitor digoxin levels and watch for loss of effect.
• Hyperglycemic agents (CCBs, corticosteroids, estrogens, phenothiazines, thiazides, thyroid hormones): May reduce or negate acarbose’s glucose-lowering effect. Re-check glycemic control when starting or stopping any of these in a patient on acarbose.

Side Effects & Overdose

Side Effects

Most adverse effects of acarbose involve the gastrointestinal tract due to delayed carbohydrate breakdown. Signs are usually mild and improve after dose adjustment.

• Flatulence: Very common, especially during the first weeks of therapy.
• Soft stools or diarrhea: Occurs when unabsorbed carbohydrates ferment in the colon.
• Abdominal discomfort: diarrhea, flatulence, and soft stools
• Transient liver enzyme elevation: Mild increases in ALT/AST when using higher doses.
• Hypoglycemia risk: Only when combined with insulin or insulin-secretagogue drugs.
• Weight loss (dogs): Reported as an adverse effect — likely from reduced calorie absorption. Monitor body weight and condition during therapy; reduce dose or discontinue if weight loss develops.

Overdose

Serious toxicity from acarbose overdose is uncommon because systemic absorption is minimal. Most clinical signs are gastrointestinal.

• Severe bloating & diarrhea: Due to excessive fermentation of unabsorbed carbohydrates.
• Marked flatulence: Typically self-limiting once food passes through the intestines.
• Hypoglycemia: Possible only if insulin was given concurrently.
• Management: Supportive care; dose reduction or temporary discontinuation. Hypoglycemia is treated with glucose (not sucrose, which acarbose blocks).

Key Notes

Important considerations when using acarbose in diabetic dogs and cats, especially when adjusting meal timing or insulin doses:

• Give with food: Acarbose must be administered immediately before a meal to block intestinal carbohydrate digestion effectively.
• Not a replacement for insulin: It only reduces post-meal glucose spikes; insulin therapy usually remains essential for diabetic control.
• Start low and titrate: Start low and titrate: Begin with 12.5–25 mg/dog or 12.5 mg/cat. Wait at least 2 weeks before increasing the dose, then titrate stepwise as tolerated.
• Not effective with reduced appetite: Works only when sufficient carbohydrates are consumed; avoid during anorexia or vomiting.
• Use caution in GI disease: Avoid in animals with IBD flare-ups, intestinal obstruction risk, colonic ulceration, or chronic severe diarrhea.
• Check liver enzymes: Periodic monitoring is recommended in long-term use or in patients receiving higher mg/dog doses.
• Treat hypoglycemia correctly: If hypoglycemia occurs, use glucose or dextrose—not table sugar—because acarbose blocks sucrose breakdown.